Pre-and Postgraduate Training in Molecular Hematology
Project Number5T32HL007088-49
Contact PI/Project LeaderOH, STEPHEN TRACY
Awardee OrganizationWASHINGTON UNIVERSITY
Description
Abstract Text
Although advances in hematology have led the way in many fields of basic and translational biomedical research,
hematologic diseases remain major threats to public health. For example, the prognosis for many hematologic
malignancies continues to be poor. Current treatments are inadequate to support a normal lifestyle for most
patients with sickle cell disease. In the U.S., at least 500,000 venous thromboembolic events, 1 million heart
attacks and 150,000 stroke deaths occur each year. At the same time, opportunities for hematology research
have never been more promising, and converting these opportunities into medical advances will depend upon
training the next generation of basic and translational hematology researchers. The Molecular Hematology train-
ing program proposes to fill this need for 5 predoctoral and 8 postdoctoral trainees per year. Predoctoral
Ph.D. and M.D./Ph.D. students follow the curriculum of the Washington University graduate school. After
passing their qualifying examination, they enter the laboratory of participating faculty Mentors for 3-4 years of
laboratory re-search to complete their dissertation. Postdoctoral Ph.D. trainees from around the world apply
to participating laboratories; postdoctoral M.D. and M.D./Ph.D. trainees usually have completed the clinical
training component of a Hematology-Oncology fellowship program at Washington University or elsewhere. The
duration of postdoc-toral training depends on prior experience. Those with Ph.D. or M.D./Ph.D degrees
typically conduct research for 2-3 years before transitioning to an independent research position, whereas
those with an M.D. degree may benefit from 3-4 years of postdoctoral training. Trainees receive intensive
mentoring and career counseling, and participate in coursework, journal clubs, and seminars. The major
facilities of the program consist of ~80,000 square feet of fully-equipped laboratory space that house the
Divisions of Hematology and Oncology, as well as extensive institutional resources for genome sequencing,
immune monitoring, informatics, animal studies, and patient-oriented clinical research. The research topics
available to trainees reflect the multidisciplinary expertise of the participating Mentors and include:
pathogenesis of hemorrhagic and thrombotic disorders; regulation of blood coagulation and fibrinolysis; gene
therapy of hemophilia and lysosomal storage diseases; phosphoinosi-tide metabolism and cell signaling
pathways; mechanisms of hematopoiesis; telomerase defects in bone marrow failure syndromes; molecular
basis for protein trafficking in mammalian cells; role of platelets and angiogenesis in metastasis; biology of
human immunodeficiency and leukemia viruses; epithelial morphogenesis; pathogene-sis of leukemia,
myelodysplastic syndrome, myeloproliferative neoplasms, and congenital neutropenia; cell cycle control;
programmed cell death in development and malignancy. Completion of this program will prepare talented
trainees for careers in basic and translational hematology research, to make discoveries that will transform the
diagnosis and treatment of hematologic diseases.
Public Health Relevance Statement
Blood diseases like leukemia, sickle cell disease, anemia, venous thrombosis, and stroke affect millions of peo-
ple in the U.S. The goal of this grant is to train a new generation of scientists who will make discoveries that
enable us to diagnose, treat, and perhaps cure these diseases.
No Sub Projects information available for 5T32HL007088-49
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5T32HL007088-49
Patents
No Patents information available for 5T32HL007088-49
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5T32HL007088-49
Clinical Studies
No Clinical Studies information available for 5T32HL007088-49
News and More
Related News Releases
No news release information available for 5T32HL007088-49
History
No Historical information available for 5T32HL007088-49
Similar Projects
No Similar Projects information available for 5T32HL007088-49